Aim: Clinical investigations of the effects of garlic preparations in hypercholesterolemia have demonstrated somewhat controversial results. These discrepancies may be due to the differences of the composition of garlic preparations and the biological response they may induce. The study was undertaken to test the hypothesis that garlic powder tablets with a prolonged mode of action promise potent biological effects. Methods: The lipid-lowering effects of time-released garlic powder tablets, Allicor (600 mg daily), were investigated in a double-blinded placebo-controlled randomized study in 42 men aged 35 − 70 with mild hypercholesterolemia. Results: Allicor treatment resulted in a moderate but statistically significant decrease in total cholesterol level that was observed after 8 and 12 weeks of active treatment. By the end of the study, total cholesterol in Allicor-treated patients had fallen by 7.6% (p 0.004) as compared to the level at randomization, and was 11.5% lower than the placebo group (p 0.005). LDL cholesterol in Allicortreated patients fell by 11.8% (p 0.002) and 13.8% (p 0.009), respectively. HDL cholesterol also increased significantly after 8 and 12 weeks of treatment. By the end of the study, HDL cholesterol in Allicor-treated patients had increased by 11.5% (p 0.013). Conclusion
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.